Abdulrazzaq Ahmed Salem AL-Maweri¹* and Essam Ahmed Al-Moraissi²

¹Department of Oral Medicine, Thamar University, Yemen
²Department of Oral and Maxillofacial Surgery, Thamar University, Yemen

*Corresponding Author: Abdulrazzaq Ahmed Salem AL-Maweri, Department of Oral Medicine, Thamar University, Yemen.

Received: March 21, 2024; Published: April 27, 2024

Abstract

Aim: The present study aimed to assess the toxicity of topical administration of two concentrations of silver nanoparticles after 28 days exposure.

Materials and Methods: Sixty males albino rats were randomly divided into the following experimental groups; Group 1 (vehicle control group): consisted of 20 healthy rats (given 0.5 ml distilled water once daily for 4 weeks topically on ratʼs tongue). Group 2: (nano-silver 50 group): consisted of 20 healthy rats (given 0.5 ml nanosilver solution50 μg/ml once daily for 4 weeks topically on ratʼs tongue in a dose of 10mg/kg). Group 3 (nano-silver 100 group): consisted of 20 healthy rats (given 0.5 ml nanosilver solution100 μg/ml once daily for 4 weeks topically on ratʼs tongue in a dose of 10mg/kg).By the end of study blood was drawn then analyzed for GOT (glutamic oxaloacetic transaminase), GPT (glutamic pyruvic transminase), CRE (creatinine), and BUN (blood urea nitrogen). Tongue, kidneys, and liver were removed, weighed, fixed, stained, and examined under light microscopy for histopathological study.

Results: The results showed that there was no significant difference in the organs weight of rats after 4 weeks of exposure, no significant changes in all four enzymes tested. Histopathologic examination revealed no pathological abnormalities in all treated animals compared to untreated healthy animals. (no inflammatory cell infiltration, no hyperplasia, no fatty degeneration ,no edema ,as well as no necrosis).

Conclusion: Silver nanoparticle (size 20 nm) in concentrations of 50,100 μg/ml in dosing volume 10mg/kg body weight are safe when applied topically in rats for 28 days.

Keywords:Silver Nanoparticle; Topical; Sub-Acute; Toxicity; Rat

References

1. Ju-Nam Y and Lead J. “Manufactured nanoparticles: an overview of their chemistry, interactions and potential environmental implications”. Science of the Total Environment1 (2008): 396-414.‏
2. De MV., et al. “Applications of nanoparticles in biology”. Advanced Materials22 (2008): 4225-4241.‏
3. Lu AH., et al. “Magnetic nanoparticles: synthesis, protection, functionalization, and application”. Angewandte Chemie International Edition8 (2007): 1222-1244.
4. Ghosh Chaudhuri R and Paria S. “Core/shell nanoparticles: classes, properties, synthesis mechanisms, characterization, and applications”. Chemical Reviews4 (2011): 2373-2433.‏
5. Sharma V., et al. “Silver nanoparticles: green synthesis and their antimicrobial activities”. Advances in Colloid and Interface Science1 (2009): 83-96.‏
6. Cheng R., et al. “Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery”. Journal of Controlled Release1 (2011): 2-12.‏
7. Huang C., et al. “Surface functionalization of super paramagnetic nanoparticles for the development of highly efficient magnetic resonance probe for macrophages”. Contrast Media and Molecular Imaging4 (2011): 298-307.‏
8. Pan J., et al. “PEGylated liposome coated QDs/mesoporous silica core-shell nanoparticles for molecular imaging”. Chemical Communications12 (2011): 3442-3444.‏
9. Thanh N and Raton B. “Magnetic Nanoparticles: From Fabrication to Clinical Applications”. CRC Press/Taylor and Francis (2011).
10. Hussain S., et al. “In vitro toxicity of nanoparticles in BRL 3A rat liver cells”. Toxicology in Vitro7 (2005): 975-983.‏
11. Kang S., et al. “Titanium dioxide nanoparticles trigger p53‐mediated damage response in peripheral blood lymphocytes”. Environmental and Molecular Mutagenesis8 (2008): 399-405.‏
12. Xia T., et al. “Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm”. Nano letters8 (2006): 1794-1807.‏
13. Lara Y., et al. “Review. Toxicological considerations of clinically applicable Nanoparticles”. Nano Today 6 (2011): 585-607.
14. Sondi I and Salopek-Bondi B. “Silver nanoparticles as antimicrobial agent: a case study on coli as a model for Gram-negative bacteria”. Journal of Colloid and Interface Science275.1 (2004): 1770-1782. 
15. Crosera M., et al. “Nanoparticle dermal absorption and toxicity: a review of the literature”. International Archives of Occupational and Environmental Health9 (2009): 1043-1055.
16. Teodoro JS., et al. “Assessment of the toxicity of silver nanoparticles in vitro: A mitochondrial perspective”. Toxicology In Vitro3 (2011): 664-705.
17. Monteiro DR., et al. “The growing importance of materials that prevent microbial adhesion: antimicrobial effect of medical devices containing silver”. International Journal of Antimicrobial Agents2 (2009): 103-110.
18. Cho KH., et al. “The study of antimicrobial activity and preservative effects of nanosilver ingredient”. Electrochimica Acta 51 (2005): 956-960.
19. Li P., et al. “Synergistic antibacterial effects of b-lactam antibiotic combined with silver nanoparticles”. Nanotechnology 16 (2005): 1912-1917.
20. Morones JR., et al. “The bactericidal effect of silver nanoparticles”. Nanotechnology 16 (2005): 2346-2353.
21. Ji JH., et al. “Evaluation of a silver nanoparticle generator using a small ceramic heater for inactivation of S. epidermidis bioaerosols”. Aerosol and Technology41 (2007): 786-793. 
22. Maynard AD. “Nanotechnology: A Research Strategy for Addressing Risk”. Washington DC: WoodrowWilson International Center for Scholars (2006).
23. KISTI (Korea Institute of Science and Technology Information): The present status of Korean nanotechnology industrialization”. Nano Weekly 210 Seoul, Korea: KISTI (2006).
24. Stebounova LV., et al. “Nanosilver induces minimal lung toxicity or inflammation in a subacute murine inhalation model”. Particle and Fibre Toxicology 1 (2011): 5.
25. Park SH., et al. “Absorption kinetics of Au and Ag nanoparticles on functionalized glass surfaces”. Microchemical Journal 63 (1999): 71-91.
26. MTR Uses Nano Technology to Enhance Hygiene Levels (2006).
27. Brayden D. “Oral vaccination in man using antigens in particles: Current status”. European Journal of Pharmaceutical Sciences 14 (2001): 183-189.
28. Oberdorster G., et al. “Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles”. Environmental Health Perspectives7 (2005): 823-839.
29. Moghimi SM., et al. “Long circulating and target specific NPs: theory to practice”. Pharmacological Reviews 53 (2001): 283-318.
30. Umamaheshwari R., et al. “Anti-helicobacter pylori effect of mucoadhesive NPS bearing amoxicillin in experimental gerbil’s model”. AAPS PharmSciTech2 (2004): 32.
31. Lee PC and Meisel D. “Adsorption and surface- enhanced raman of dyes on silver and gold sols”. The Journal of Physical Chemistry A 86 (1982): 3391-3395.
32. OECD: Acute Oral Toxicity-Acute Toxic Class Method”. OECD Guideline for Testing of Chemicals 12 (2002): 1-14.
33. Ingelheim Boehringer: Revised Guides for Organ Sampling and Trimming in Rats and Mice - Part (1) (2003): 91-106.
34. De Lima R., et al. “Silver nanoparticles: a brief review of cytotoxicity and genotoxicity of chemically and biogenically synthesized nanoparticles”. Journal of Applied Toxicology 11 (2012): 867-879.
35. Kim Y., et al. “Twenty-eight-day oral toxicity, genotoxicity, and gender related tissue distribution of silver nanoparticles in Sprague- Dawley rats”. Inhalation Toxicology 6 (2008): 575-583.
36. Jain J., et al. “Silver nanoparticles in therapeutics:development of an antimicrobial gel formulation for topical use”. Molecular Pharmaceutics 5 (2009): 1388-1401.
37. Korani S., et al. “Acute and subchronic dermal toxicity of nanosilver in guinea pig”. International Journal of Nanomedicine 6 (2011): 855-862.
38. Mohammad K., et al. “Assessment of dermal exposure and histopatholoic changes of different sized nano-silver in healthy adult rabbits. International Conference on Safe Production and Use of Nanomaterials”. Journal of Physics: Conference Series 304 (2011): 1-9.
39. Sardari R., et al. “Toxicological effects of silver nanoparticles in rats”. African Journal of Microbiology Research 27 (2012): 5587-5593.
40. Park E., et al. “Repeated-dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles”. Environmental Toxicology and Pharmacology 2 (2010): 162-168.‏
41. Javad C., et al. “In vivo effect of silver nanoparticles on serum ALT, AST and ALP activity in male and female mice”. Australian Journal of Basic and Applied Sciences 1 (2013): 171-177.
42. Abdelaziz H., et al. “Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates”. Journal of Controlled Release 269 (2018): 374-392.
43. Jumelle C., et al. “Advances and limitations of drug delivery systems formulated as eye drops”. Journal of Controlled Release 321 (2020): 1-22.
44. Sudhakar Y., et al. “Buccal bioadhesive drug delivery a promising option for orally less efficient drugs”. Journal of Controlled Release 114 (2006): 15-40.
45. Patel VF., et al. “Advances in oral transmucosal drug delivery”. Journal of Controlled Release 153 (2011): 106-116.
46. Jacobsen J., et al. “TR146 cells as a model for human buccal epithelium. II Optimisation and use of a cellular sensitivity MTS/PMS assay”. International Journal of Pharmaceutics 141 (1996): 217-225.
47. Hua S. “Advances in Nanoparticulate Drug Delivery Approaches for Sublingual and Buccal Administration”. Frontiers in Pharmacology 10 (2019): 1328.
48. Hadrup N., et al. “Subacute oral toxicity investigation of nanoparticulate and ionic silver in rats”. Archives of Toxicology4 (2012): 543-551.
49. Collart D., et al. “Efficacy of oligodynamic metals in the control of bacteria growth in humidifier water tanksand mist droplets”. Journal of Water and Health 2 (2006): 149-156.
50. Bouwmeester H., et al. “Review of health safety aspects of nanotechnologies in food production”. Regulatory Toxicology and Pharmacology 1 (2009): 52-62.
51. Roblegg E., et al. “Evaluation of a physiological in vitro system to study the transport of nanoparticles through the buccal mucosa”. Nanotoxicology 4 (2012): 399-413.
52. Patil RS., et al. “One-pot synthesis of PVA-capped silver nanoparticles their characterization and biomedical application”. Advances in Natural Sciences: Nanoscience and Nanotechnology1 (2012): 015013.‏
53. Garcia T., et al. “Oral subchronic exposure to silver nanoparticles in rats”. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association 92 (2016): 177-187.
54. Padole N and Avari J. “Synthesis of silver nanoparticles for antibacterial activity against Staphylococcus aureus and Escherichia coli”. Asian Journal of Pharmaceutical Research and Development5 (2021): 67-73.
55. Nada Tarek Zaki., et al. “The Possible Protective Role of Vitamin E on the Induced Silver Nanoparticles Toxicity on Filiform and Circumvallate Tongue Papillae of Albino Rats Histological and Immunohistochemical Study”. Journal of Chemical Health Risks 1 (2021): 63-74.
56. Nghilokwa E., et al. “Sub-acute and chronic toxicity of silver nanoparticles synthesized by Azadirachta indica extract”.‏ African Journal of Biotechnology 6 (2020): 320-331.
57. Ji Hyun., et al. “Blood Biochemical and Hematological Study after Subacute Intravenous Injection of Gold and Silver Nanoparticles and Coadministered Gold and Silver Nanoparticles of Similar Sizes”. BioMed Research International (2018): 8460910-8460910.
58. Hendrickson OD., et al. “Toxicity of nanosilver in intragastric studies: Biodistribution and metabolic effects”. Toxicology letters 241 (2016): 184-192.
59. Wilding LA., et al. “Repeated dose (28-day) administration of silver nanoparticles of varied size and coating does not significantly alter the indigenous murine gut microbiome”. Nanotoxicology5 (2016): 513-520.
60. Yun JW., et al. “Comparative toxicity o silicon dioxide, silver and iron oxide nanoparticles after repeated oral administration to rats”. Journal of Applied Toxicology 35 (2015): 681e693.
61. Hadrup N and Lam HR. “Oral toxicity of silver ions, silver nanoparticles and colloidal silver- a review”. Regulatory Toxicology and Pharmacology68 (2014): 1e7.
62. Weaver JL., et al. “Evaluating the potential of gold, silver, and silica nanoparticles to saturate mononuclear phagocytic system tissues under repeat dosing conditions”. Particle and Fibre Toxicology 14 (2017): 25.
63. Tyner KM., et al. “How has CDER prepared for the nano revolution? A Review of risk assessment, regulatory research, and guidance activities”. AAPS Journal 19 (2017): 1071-1083.

Citation

Citation: Abdulrazzaq Ahmed Salem AL-Maweri and Essam Ahmed Al-Moraissi. “Subacute Toxicological Profile Assessment of Silver-Nanoparticles After Topical Mucosal Application in Albino Rats".Acta Scientific Dental Sciences 8.5 (2024): 82-91.

Copyright

Copyright: © 2024 Abdulrazzaq Ahmed Salem AL-Maweri and Essam Ahmed Al-Moraissi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.